Additionally, the difference in the recommendations from the UKCGG/UKGTN meeting and the TD have resulted in further variation in practice, particularly for the moderate risk breast cancer predisposition genes ATM and CHEK2. This evidence concerns the gene CHEK2 and breast carcinoma.